| HS Code | 302625 |
| Product Name | Propetamphose Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Cas Number | 31218-83-4 |
| Molecular Formula | C10H20NO4PS |
| Molecular Weight | 281.31 g/mol |
| Physical State | Clear to pale yellow oily liquid |
| Density | 1.142 g/cm3 at 20°C |
| Boiling Point | 87–89°C at 0.005 mmHg |
| Water Solubility | 110 mg/L at 20°C (slightly soluble) |
| Organic Solubility | Soluble in acetone, ethanol, xylene and most organic solvents |
| Stability | Stable under normal storage conditions; gradually hydrolyzed in alkaline conditions |
| Storage Conditions | Store in the original tightly closed container in a cool, dry, well-ventilated area away from heat, moisture, and direct sunlight |
| Pharmacological Class | Organophosphate insecticide and acaricide |
| Mechanism Of Action | Inhibits acetylcholinesterase in parasites, causing accumulation of acetylcholine, neuromuscular paralysis, and death |
| Veterinary Indications | Treatment and control of fleas, ticks, lice, blowfly larvae, and mange mites in livestock and companion animals |
| Target Species | Cattle, sheep, goats, pigs, and dogs |
| Available Dosage Forms | Tablets, injections, capsules, powders, granules, premix, and solutions |
As an accredited Propetamphose Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Propetamphose Veterinary Grade API supplied in sealed, moisture-proof, tamper-evident containers for various dosage forms. Quantity: 25 kg. |
| Container Loading (20′ FCL) | Propetamphose Veterinary Grade API packed in sealed drums/pails, palletized, securely loaded into a 20' FCL container for safe transportation. |
| Shipping | Propetamphose Veterinary Grade API is shipped as a hazardous, toxic substance in sealed, light-resistant containers. Transport requires temperature-controlled, ventilated conditions, away from moisture and incompatible materials. All shipments comply with dangerous goods regulations, with proper labeling and documentation for pharmaceutical use in tablets, injections, capsules, powders, granules, premix, or solutions. |
| Storage | Store Propetamphos Veterinary Grade API in tightly sealed, original containers in a cool, dry, well-ventilated area, away from direct sunlight, heat, and open flames. Protect from moisture. Ensure the area is secure and inaccessible to unauthorized personnel or animals. Maintain room temperature, with proper labeling and spill control protocols. |
| Shelf Life | Shelf life is typically 24–36 months when stored in tightly sealed, original containers under controlled, recommended conditions. |
Propetamphos is an organophosphate acaricide/insecticide used in veterinary and agricultural biosecurity applications. The API is processed into emulsifiable concentrates, suspension concentrates, wettable powders, spray solutions, and granular baits. Documented routes of use are topical and environmental; tablet, capsule, injectable, and feed premix formats are not supported by current public veterinary monographs and are treated separately as boundary assessments. The sections that follow separate application classes by process equipment and target site rather than by packaging type, because packaging type alone does not determine process limits.
Plunge dipping for Psoroptes ovis, Bovicola ovis, Melophagus ovinus, and Lucilia sericata starts with a metered emulsifiable concentrate diluted into a constant-level dip sump fitted with a draining pen and a post-dip holding area. The primary process boundary is the pH of the dip wash; alkaline pH above 8.5 accelerates hydrolysis of the organophosphate ester and reduces active concentration faster than the product label anticipates. Bath pH and active content must be measured before charge and after each operational interruption using a validated liquid chromatographic assay; visual reconstitution alone cannot detect active loss. Plunge contact time must achieve full fleece saturation; a minimum immersion period of 60 seconds is the standard operational target for adult sheep under UK-type dipping conditions, but the label remains the controlling statement. Carry-out volume is a second major loss route; wool grease, straw, and faeces adsorb the active and contribute to stripping, so replenishment should be based on assayed active concentration rather than simple volume replacement. Published data for propetamphos-specific stripping rates per hundred sheep is limited; the operational assay interval should therefore be shortened for long-wool breeds and wet animals. The dip sump should be charged only with water that is free of suspended clay and excessive hardness; where site water contains high calcium or magnesium hardness, a pre-trial emulsion stability test according to CIPAC MT 36 should be run before the flock enters the facility. Operators require chemical-resistant nitrile gloves meeting EN 374, impervious coveralls, and face protection because the organophosphate is absorbed through skin and mucous membranes. Spent dip must be collected and treated as hazardous aqueous waste; release into watercourses is incompatible with the aquatic toxicity profile and is controlled by national sheep dip legislation. Disposal risk assessment should include OECD 203 acute fish toxicity and OECD 209 activated sludge inhibition data.
Stable bands, stanchion posts, feed barriers, and non-porous transport cage surfaces receive residual organophosphate barriers only where the registration permits crack-and-crevice or banded surface treatment. The working liquid is applied with a low-pressure hydraulic sprayer fitted with a pressure gauge; nozzle pressure is held between 2 bar and 3 bar to generate a coarse spray with a volume median diameter above 150 µm, as defined by spray classification methods such as ASABE S572.1. Lime-washed or alkaline surfaces shorten residual activity; the surface pH should be recorded before application because alkaline substrates accelerate ester degradation. Heavy dust and manure should be removed by dry scraping before spraying, because organophosphate active binds to organic matter and becomes unavailable for insect contact. Application rate, re-entry interval, and animal separation requirements are product-specific and must be taken from the authorised label; no universal surface loading value is valid across all national clearances. The main process failure observed on farm is underestimating surface area; calibration should be performed with clean water over a measured area before the active dilution is loaded into the tank. The tank should not be left overnight with remaining alkaline or oxygen-rich water that can hydrolyse the active during standby. The filling area must not discharge to drains without a valve-controlled containment system.
Granular propetamphos baits are applied as scatter bait or bait stations in manure pits, refuse bays, empty animal housing, and fly aggregation zones where Musca domestica pressure is localised. The carrier should be a non-dusty granule with a sieve cut between 0.25 mm and 2.0 mm; finer particles become airborne and are not acceptable for baiting because they reduce placement accuracy and create inhalation exposure. Carrier moisture below 5% w/w is required to prevent clumping, microbial growth, and active degradation during storage. The granule must be conditioned with a feeding attractant and an ultraviolet protectant if the product is exposed to direct sunlight in open bays; published data for propetamphos-specific photolysis half-life on granule surfaces is limited, but general organophosphate photodegradation supports shaded placement as a conservative boundary. Broadcast application must be calibrated by pan-collection across the target surface before product is released; the label application rate is expressed as mass of bait per square metre, not as active concentration alone. Bait stations must be secured against access by livestock, dogs, and birds, and the product must be protected from rain or sprinkler wash-down. The use of propetamphos as a granule is an environmental insecticide application, not a feed premix; in the EU, placement as a biocide falls under the Biocidal Products Regulation (EU) No 528/2012, product-type 18, and the label must be checked for authorised use sites. Rotation with non-organophosphate bait modes is recommended as a resistance-management measure only when compatible with national product labels. The main process limit is the presence of competing food sources; wet manure and spilt feed around placement zones reduce bait station visits and lower efficacy.
Recirculating spray races and hand jetting wands apply diluted propetamphos solution to the back, flanks, breech, and head of sheep before fly pressure or after shearing. The spray-race pump is operated at a measured 2–3 bar; flat-fan nozzles deliver a coarse droplet distribution above 150 µm, while hollow-cone nozzles increase the fraction of driftable fines and should be avoided unless the race is fully enclosed. Full skin wetting to the base of the wool is the target visual endpoint; penetration failure on the backline is the primary field defect, particularly on long-wool breeds. The total liquid volume per animal is label-dependent and must reflect fleece length, breed, and time since shearing; published data for propetamphos-specific volume requirements in adult long-wool sheep under wet conditions is limited. The system should be inspected daily for nozzle wear because a 10% increase in orifice flow area shifts the droplet spectrum toward finer spray and increases operator exposure. The race must be operated on a sealed concrete apron with no direct drain to surface water; run-off carries organophosphate residues and is treated as hazardous liquid. Animals should not be moved through the race until the pump pressure has stabilised, and the pressure gauge should be checked after each group of animals. Operator cholinesterase monitoring is an appropriate occupational health boundary where daily exposure occurs; the frequency follows national veterinary chemical safety arrangements. The product should not be mixed with alkaline detergents or amine-based tank cleaners because these can promote ester hydrolysis in the working solution.
Tablet, capsule, injectable, and oral premix formats are not identified as approved propetamphos applications in current public veterinary formularies. The organophosphate mode of action and the safety package expected under VICH GL43 for systemic dosage forms are not represented by a published target animal dossier for oral or parenteral use. If a solid oral matrix is prepared for exploratory formulation work, the API would need to be evaluated for compatibility with binder systems, moisture, and drying conditions; however, published data for propetamphos wet granulation stability, compressibility, and degradation products in tablet matrices is limited. Injectable solutions would require a solvent system that maintains chemical stability and limits injection-site cholinesterase depression; no standard pH, solubility, or tissue tolerance profile is available for propetamphos injectable formulations in target species. Capsule formulations face the same absent oral safety and efficacy data. Premix use in animal feed is not supported by the EU feed additive framework under Regulation (EC) No 1831/2003; propetamphos is not authorised as a feed additive or medicated premix. The distinction between an environmental granular bait and a feed premix is regulatory and must not be conflated. Powders are limited to potential environmental dust or crack-and-crevice use where a national label exists; direct animal dusting is not a default approved route. Any request for tablet, capsule, injectable, or premix propetamphos should be checked against the authorised national product label, MRL status, and target animal safety file before formulation work begins.
Competitive Propetamphose Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Propetamphose Veterinary Grade API (ISO common name: propetamphos; CAS 31218-83-4) is a defined-purity organophosphorothioate active substance supplied under a veterinary-grade model that is separated from technical-grade material by residual solvent control, related-substance monitoring, and container-closure documentation suitable for good manufacturing practice use. The molecular formula is C10H20NO4PS with a relative molecular mass of 281.31 g/mol. The API is intended for incorporation into tablets, injections, capsules, powders, granules, premixes, and solutions; however, the route-specific specification must be adjusted for the hydrolytic sensitivity of the phosphoramidothioate and vinyl ester moieties. Procurement specifications should require a certificate of analysis that identifies the grade code, assay basis, micronization status, and retest interval rather than relying on a generic trade designation alone.
Because the molecule is a lipophilic organophosphorothioate with limited aqueous solubility, preformulation work must define solubility in the intended vehicle and the pH-dependent hydrolysis boundary rather than assume the API is interchangeable with other organophosphate actives. The phosphoramidothioate center requires oxidative desulfuration to the corresponding oxon for acetylcholinesterase inhibition; this creates a delayed onset characteristic that influences formulation design, residue modelling, and safety handling. Published data for oral tablet delivery of this specific chemical entity is limited, so forced degradation studies under ICH Q1B and VICH stability principles are required before setting manufacturing controls for each dosage form. Partition behaviour should be confirmed by OECD 117 HPLC method; a single log value should not be transferred between suppliers without verifying the impurity profile.
The first identification gate is the ISO 1750 common name propetamphos, which connects the product to the internationally harmonised pesticide naming system and distinguishes it from proprietary names. The organophosphorothioate class is defined by a P=S thiono group rather than a P=O oxon group; this structural distinction is analytically detectable by infrared spectroscopy and phosphorus-31 nuclear magnetic resonance. Identity testing should include chromatographic retention time against an ISO 17034 reference material, and the certificate should state whether the reference material is a neat substance or a certified solution. Regulatory classification follows the target jurisdiction’s veterinary drug or ectoparasiticide framework; the API is not intended for human medicinal use, and the label must be controlled accordingly.
Specification setting for a veterinary API of this type is governed by the ICH Q6A decision tree where no harmonised pharmacopoeial monograph exists. The manufacturer should demonstrate that the active substance is stable under the proposed packaging, that the analytical methods are validated under ICH Q2(R1), and that impurity limits are justified by toxicological assessment. The model release criteria in the table below are presented as a specification framework rather than as a universal certificate; each lot must be tested against vendor-established limits that are aligned with the intended route of administration.
| Parameter | Example acceptance criterion | Reference method |
|---|---|---|
| Appearance | Clear to pale yellow oil or spray-dried carrier dispersion; free of visible particulate matter | Visual inspection, Ph. Eur. 2.9.20 |
| Identification | HPLC retention time matches propetamphos reference; IR spectrum matches library | Validated HPLC, infrared absorption |
| Assay | 98.0%–102.0% on dried basis | HPLC area normalization against external standard |
| Related substances | Total impurities ≤ 2.0%; unspecified impurity ≤ 0.5% | HPLC with 0.1% formic acid mobile phase |
| Water content | ≤ 0.5% w/w for solid oral grades; route-specific limit for lyophilised injections | Karl Fischer titration, Ph. Eur. 2.5.12 |
| Residual solvents | Class 1 solvents absent; Class 2 solvents within ICH Q3C(R8) options | Headspace gas chromatography |
| Elemental impurities | Limits assigned per ICH Q3D(R2) based on route of administration | Acid digestion followed by ICP-MS |
| Particle size for solid dosage forms | D90 acceptance range set during process validation; powder flow evaluated by Ph. Eur. 2.9.36 | ISO 13320:2020 laser diffraction |
| Microbial quality for non-sterile use | TAMC ≤ 1000 CFU/g; TYMC ≤ 100 CFU/g; absence of Escherichia coli | Ph. Eur. 2.6.12, 2.6.13 |
The route of administration changes the analytical burden even when the active substance is identical. For tablets and capsules, the API specification must be supplemented by pharmacopoeial tests on the finished dosage form: uniformity of dosage units per USP <905>, disintegration per USP <701>, and dissolution per USP <711> where a suitable dissolution medium has been qualified. For injectable solutions or suspensions, the finished product must additionally meet USP <788> particulate matter limits, USP <85> bacterial endotoxins, and USP <71> sterility. The API itself is not sterile unless the vendor supplies an irradiated or aseptic grade under a validated batch record.
Residual water is a critical release parameter because organophosphorothioates undergo hydrolysis in the presence of moisture; the degradation products include the desulfurated oxon and phosphorus-containing acid derivatives, which must be identified in the related-substances profile. The specification should include a specific test for the oxon metabolite at a low reporting threshold, because even small increases in the oxon content can alter the acute toxicological profile. Bulk API stored in original containers at ambient humidity above 60% RH should be limited by a defined hold time or transferred to a dry nitrogen environment. Sodium sulfate or molecular sieves should not be added to the API without compatibility data; their use can create local pH shifts that accelerate decomposition.
Direct compression of the API is generally unsuitable at typical veterinary dose levels because the neat active substance is an oil and cannot form a free-flowing, compressible powder without a carrier. Fluid-bed wet granulation with povidone or copovidone is preferred when the final product is a tablet or capsule, provided the inlet air temperature is kept below the degradation threshold and the granulation solvent is removed rapidly. Dry blending of the liquid API with microcrystalline cellulose and colloidal silicon dioxide is feasible only after pre-adsorption onto a porous carrier such as silica or calcium silicate; the blend must be tested for segregation, flow, and content uniformity before compression. Capsule filling should be controlled by weight rather than volume if the bulk density changes because of residual solvent content. Granulation end-point should be set by torque or power consumption rather than by subjective visual appearance.
Aqueous solutions undergo accelerated hydrolysis in the high-pH region, so the injectable formulation must either use a nonaqueous vehicle or be formulated below the pH boundary established by forced degradation data. Propylene glycol, medium-chain triglycerides, and glyceryl monocaprylocaprate are candidate vehicles, but each requires compatibility screening for phase separation, peroxide content, and autoclave stability. Terminal sterilisation at 121°C for 15 minutes is acceptable only if the API shows less than the permitted degradation product formation under that thermal load; if the molecule is heat-labile, sterile filtration through a 0.22 µm filter followed by aseptic filling is required. Filter compatibility must be confirmed because low-polarity solvents can extract filter additives or cause membrane swelling.
For injectable suspensions, the particle size distribution must be controlled by laser diffraction or microscopic counting, and the suspension must be evaluated for sedimentation volume and resuspendability after storage. Wetting agents such as polysorbate 80 can improve dispersibility but may interact with the organophosphate ester; forced degradation studies should include a vehicle-free control to separate the effect of the surfactant. The finished injectable product must meet particulate matter limits even after stressing at low temperature, because a poorly stabilised suspension can form needle-like crystals or agglomerates that exceed USP <788> thresholds. Bacterial endotoxin testing is mandatory for intravenously administered formulations and may also be required for intramammary or subcutaneous routes depending on the regulatory filing.
For feed premixes and oral powders, the API is adsorbed onto a carrier selected for dust control, flowability, and chemical inertness. The adsorption step should be conducted in a closed blender under negative pressure, with the API temperature maintained below the point at which the oily active substance migrates to the surface of the carrier. Content uniformity in premix packaging is evaluated by sampling at defined intervals during the blending run; the acceptance range should be derived from batch homogeneity data rather than from a universal fixed value. Cross-contamination control requires documented cleaning validation because organophosphate residues can be transferred to non-target feed batches. The cleaning limit should be established using toxicological risk assessment, and the analytical method should detect the parent compound and the oxon metabolite at the relevant residue threshold.
| Active substance | CAS | Activation pathway | Stability constraint | Formulation implication |
|---|---|---|---|---|
| Propetamphos | 31218-83-4 | Thiono-to-oxon conversion required | Vinyl ester hydrolysis at elevated pH | Low-moisture granulation; nonaqueous injectable vehicle preferred |
| Malathion | 121-75-5 | Carboxylesterase detoxification | Alkaline ester cleavage | Low-moisture packaging; buffered suspensions are restricted |
| Diazinon | 333-41-5 | Thiono activation required | Alkaline hydrolysis; high volatility | Closed processing; odour and vapour controls |
| Dichlorvos | 62-73-7 | Direct oxon activity | Rapid hydrolysis in water | Short in-use stability; nonaqueous or encapsulated delivery only |
Addition of oxidising agents or strongly alkaline excipients is incompatible with the phosphoramidothioate function; the thiono sulfur can be oxidised to the oxon, which increases the acute anticholinesterase load and shifts the residue profile. Formulation with sodium bicarbonate, carbonate buffers, or hypochlorite-based sanitizers is therefore restricted unless the process includes removal of the reactive agent before the API is added. Equipment contact surfaces should be verified to be free of oxidising residues after cleaning. The final manufacturing step should include a stability-indicating assay for the parent compound and the oxon metabolite in the chosen packaging configuration, and the batch release data should record both values.